Crescent Biopharma, Inc. (CBIO) Stock Score, Valuation & Financial Research
Crescent Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for CBIO
Crescent Biopharma, Inc. currently has a Wall Street Score of 23/100. The stored market price is $19.68. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Crescent Biopharma, Inc. does
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $19.68
- Market capitalization:
- $731.0M
- Revenue:
- $11.9M
- Net income:
- $-163.0M
- Free cash flow:
- $-144.5M
- Cash:
- $171.6M
- Total debt:
- $1.4M
- EPS:
- -7.58
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-144.5M, showing cash burn in the current stored period.
- The balance sheet shows $171.6M of cash versus $1.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: CBIO decreased 0.1 points because some fundamentals weakened.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CBIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.